• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $OMCL

    Omnicell Inc.

    Subscribe to $OMCL
    $OMCL
    Computer Manufacturing
    Technology

    Omnicell, Inc., together with its subsidiaries, provides medication management automation solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System, a building block of autonomous pharmacy vision; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems. It also provides point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; Omnicell Interface Software that offers interface and integration between its medication-use products or supply products, and a healthcare facility's in-house information management systems; and robotic dispensing systems for handling the stocking and retrieval of boxed medications. In addition, the company provides automated systems to help pharmacies in filling its multimed adherence packaging based on individual patient medication orders; single dose automation solutions to fill and label for incoming prescriptions; semi-automated filling equipment for the long-term care institutional pharmacy; and medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings. Further, it offers EnlivenHealth Patient Engagement, a web-based nexus of solutions. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Mountain View, California.

    IPO Year: 2001

    Exchange: NASDAQ

    Website: omnicell.com

    Recent Analyst Ratings for Omnicell Inc.

    DatePrice TargetRatingAnalyst
    10/31/2024$44.00 → $57.00Buy → Neutral
    BofA Securities
    8/2/2024$26.00 → $39.00Underweight → Equal Weight
    Barclays
    1/3/2024$33.00Underweight
    Barclays
    11/3/2023$39.00 → $28.00Underweight → Equal Weight
    Wells Fargo
    11/3/2023Buy → Neutral
    BTIG Research
    11/3/2023$70.00 → $39.00Neutral → Overweight
    Piper Sandler
    10/11/2023Overweight → Sector Weight
    KeyBanc Capital Markets
    9/26/2023$56.00 → $39.00Underweight
    Wells Fargo
    8/2/2023$66.00 → $70.00Overweight → Neutral
    Piper Sandler
    7/20/2023$65.00 → $56.00Overweight → Underweight
    Wells Fargo
    See more ratings

    Omnicell Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • EVP, Chief Operating Officer Njoku Nnamdi was granted 37,409 shares, increasing direct ownership by 70% to 90,929 units (SEC Form 4)

      4 - OMNICELL, INC. (0000926326) (Issuer)

      3/18/25 4:14:39 PM ET
      $OMCL
      Computer Manufacturing
      Technology
    • CHAIRMAN, PRESIDENT AND CEO Lipps Randall A bought $349,874 worth of shares (10,561 units at $33.13) and was granted 79,494 shares, increasing direct ownership by 28% to 413,104 units (SEC Form 4)

      4 - OMNICELL, INC. (0000926326) (Issuer)

      3/18/25 4:13:27 PM ET
      $OMCL
      Computer Manufacturing
      Technology
    • EVP&CHIEF LEGAL/ADMIN OFFICER Manley Corey J was granted 22,445 shares and covered exercise/tax liability with 71 shares, increasing direct ownership by 23% to 120,281 units (SEC Form 4)

      4 - OMNICELL, INC. (0000926326) (Issuer)

      3/18/25 4:12:23 PM ET
      $OMCL
      Computer Manufacturing
      Technology
    • EVP&CHIEF LEGAL/ADMIN OFFICER Manley Corey J was granted 56,268 shares and covered exercise/tax liability with 4,697 shares, increasing direct ownership by 111% to 97,907 units (SEC Form 4)

      4 - OMNICELL, INC. (0000926326) (Issuer)

      3/11/25 4:27:06 PM ET
      $OMCL
      Computer Manufacturing
      Technology
    • EVP & CFO Etta Nchacha was granted 66,633 shares and covered exercise/tax liability with 5,368 shares, increasing direct ownership by 87% to 132,023 units (SEC Form 4)

      4 - OMNICELL, INC. (0000926326) (Issuer)

      3/11/25 4:26:26 PM ET
      $OMCL
      Computer Manufacturing
      Technology
    • CHAIRMAN, PRESIDENT AND CEO Lipps Randall A was granted 188,794 shares and covered exercise/tax liability with 18,571 shares, increasing direct ownership by 111% to 323,049 units (SEC Form 4)

      4 - OMNICELL, INC. (0000926326) (Issuer)

      3/11/25 4:25:29 PM ET
      $OMCL
      Computer Manufacturing
      Technology
    • EVP&CHIEF LEGAL/ADMIN OFFICER Manley Corey J covered exercise/tax liability with 2,545 shares, decreasing direct ownership by 5% to 46,336 units (SEC Form 4)

      4 - OMNICELL, INC. (0000926326) (Issuer)

      3/4/25 4:06:34 PM ET
      $OMCL
      Computer Manufacturing
      Technology
    • CHAIRMAN, PRESIDENT AND CEO Lipps Randall A covered exercise/tax liability with 6,652 shares, decreasing direct ownership by 4% to 152,826 units (SEC Form 4)

      4 - OMNICELL, INC. (0000926326) (Issuer)

      3/4/25 4:04:59 PM ET
      $OMCL
      Computer Manufacturing
      Technology
    • EVP & CFO Etta Nchacha covered exercise/tax liability with 2,427 shares, decreasing direct ownership by 3% to 70,758 units (SEC Form 4)

      4 - OMNICELL, INC. (0000926326) (Issuer)

      3/4/25 4:04:02 PM ET
      $OMCL
      Computer Manufacturing
      Technology
    • CHAIRMAN, PRESIDENT AND CEO Lipps Randall A covered exercise/tax liability with 756 shares, decreasing direct ownership by 0.47% to 159,478 units (SEC Form 4)

      4 - OMNICELL, INC. (0000926326) (Issuer)

      2/18/25 4:10:41 PM ET
      $OMCL
      Computer Manufacturing
      Technology

    Omnicell Inc. SEC Filings

    See more
    • SEC Form 10-Q filed by Omnicell Inc.

      10-Q - OMNICELL, INC. (0000926326) (Filer)

      5/7/25 4:03:30 PM ET
      $OMCL
      Computer Manufacturing
      Technology
    • Omnicell Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - OMNICELL, INC. (0000926326) (Filer)

      5/6/25 6:34:17 AM ET
      $OMCL
      Computer Manufacturing
      Technology
    • SEC Form DEF 14A filed by Omnicell Inc.

      DEF 14A - OMNICELL, INC. (0000926326) (Filer)

      4/3/25 5:09:39 PM ET
      $OMCL
      Computer Manufacturing
      Technology
    • Omnicell Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - OMNICELL, INC. (0000926326) (Filer)

      3/12/25 8:40:30 AM ET
      $OMCL
      Computer Manufacturing
      Technology
    • Omnicell Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - OMNICELL, INC. (0000926326) (Filer)

      3/4/25 4:32:02 PM ET
      $OMCL
      Computer Manufacturing
      Technology
    • SEC Form 10-K filed by Omnicell Inc.

      10-K - OMNICELL, INC. (0000926326) (Filer)

      2/27/25 4:27:55 PM ET
      $OMCL
      Computer Manufacturing
      Technology
    • Omnicell Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - OMNICELL, INC. (0000926326) (Filer)

      2/6/25 6:46:41 AM ET
      $OMCL
      Computer Manufacturing
      Technology
    • Omnicell Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits

      8-K - OMNICELL, INC. (0000926326) (Filer)

      11/25/24 5:15:15 PM ET
      $OMCL
      Computer Manufacturing
      Technology
    • Omnicell Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

      8-K - OMNICELL, INC. (0000926326) (Filer)

      11/18/24 5:28:24 PM ET
      $OMCL
      Computer Manufacturing
      Technology
    • SEC Form 10-Q filed by Omnicell Inc.

      10-Q - OMNICELL, INC. (0000926326) (Filer)

      11/8/24 4:05:00 PM ET
      $OMCL
      Computer Manufacturing
      Technology

    Omnicell Inc. Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CHAIRMAN, PRESIDENT AND CEO Lipps Randall A bought $349,874 worth of shares (10,561 units at $33.13) and was granted 79,494 shares, increasing direct ownership by 28% to 413,104 units (SEC Form 4)

      4 - OMNICELL, INC. (0000926326) (Issuer)

      3/18/25 4:13:27 PM ET
      $OMCL
      Computer Manufacturing
      Technology

    Omnicell Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more

    Omnicell Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    Omnicell Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Omnicell Announces First Quarter 2025 Results

      Omnicell delivers solid first quarter financial results Results exceed previously issued first quarter 2025 guidance for total revenues and non-GAAP EPS Updates full year 2025 non-GAAP EBITDA and non-GAAP EPS guidance Omnicell, Inc. (NASDAQ:OMCL) ("Omnicell," "we," "our," "us," "management," or the "Company"), a leader in transforming the pharmacy and nursing care delivery model, today announced results for its first quarter ended March 31, 2025. "We delivered strong financial results for the first quarter of 2025, exceeding our previously provided guidance ranges for both revenue and earnings, which we believe reflects customers embracing the industry-defined vision of the Autonomous P

      5/6/25 6:30:00 AM ET
      $OMCL
      Computer Manufacturing
      Technology
    • Omnicell to Release First Quarter 2025 Financial Results on May 6, 2025

      Omnicell, Inc. (NASDAQ:OMCL), a leader in transforming the pharmacy and nursing care delivery model, will release its financial results for the first quarter 2025, before market open on Tuesday, May 6, 2025. The Company will host a conference call and webcast to discuss its financial results at 8:30 a.m. ET that same day. All interested parties are invited to listen to the live call and presentation by dialing (800) 715-9871 in the U.S. or (646) 307-1963 in international locations. The Conference ID is 7437144. A link to the live and archived webcast will also be available on the Investor Relations section of Omnicell's website at https://ir.omnicell.com/events-and-presentations/. About O

      4/14/25 4:01:00 PM ET
      $OMCL
      Computer Manufacturing
      Technology
    • Omnicell Welcomes Perry A. Genova, PhD, as Chief Technology Officer

      Medical device, pharmaceutical, and life sciences expert tapped to lead Company's technology strategy and global engineering organization Omnicell, Inc. (NASDAQ:OMCL) ("Omnicell" or the "Company"), a leader in transforming the pharmacy and nursing care delivery model, today announced that Perry A. Genova, PhD, will join the Company as Senior Vice President, Chief Technology Officer, effective March 31, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250324514095/en/Perry A. Genova, PhD, will join the Company as Senior Vice President, Chief Technology Officer, on March 31, 2025. Dr. Genova will lead Omnicell's technology str

      3/24/25 4:01:00 PM ET
      $OMCL
      Computer Manufacturing
      Technology
    • Omnicell Announces Chief Financial Officer Transition

      Company Reiterates First Quarter and Full Year 2025 Guidance Omnicell, Inc. (NASDAQ:OMCL) ("Omnicell," "we," "our," "us," "management," or the "Company"), a leader in transforming the pharmacy and nursing care delivery model, today announced that Nchacha Etta will be stepping down from his role as Executive Vice President and Chief Financial Officer, effective September 15, 2025 or until a successor is named. Mr. Etta will continue to serve as Executive Vice President and Chief Financial Officer while Omnicell searches for a new Chief Financial Officer and will work to ensure a smooth transition of his role and responsibilities. The Company has commenced a national search for his successor

      3/12/25 8:30:00 AM ET
      $OMCL
      Computer Manufacturing
      Technology
    • Omnicell Announces Fiscal Year and Fourth Quarter 2024 Results

      Omnicell delivers strong fourth quarter financial results Results exceed previously issued full year guidance for bookings, total revenues, and non-GAAP EBITDA Omnicell, Inc. (NASDAQ:OMCL) ("Omnicell," "we," "our," "us," "management," or the "Company"), a leader in transforming the pharmacy and nursing care delivery model, today announced results for its fiscal year and fourth quarter ended December 31, 2024. "We delivered solid financial results for the fourth quarter of 2024, including returning to year-over-year revenue growth. We are pleased with the improved execution of the business throughout 2024, including strong free cash flows achieved in the year," stated Randall Lipps, ch

      2/6/25 6:30:00 AM ET
      $OMCL
      Computer Manufacturing
      Technology
    • Omnicell to Release Fourth Quarter and Full Year 2024 Financial Results on February 6, 2025

      Omnicell, Inc. (NASDAQ:OMCL), a leader in transforming the pharmacy and nursing care delivery model, will release its financial results for the fourth quarter and full year 2024, before market open on Thursday, February 6, 2025. The Company will host a conference call and webcast to discuss its financial results at 8:30 a.m. ET that same day. All interested parties are invited to listen to the live call and presentation by dialing (800) 715-9871 in the U.S. or (646) 307-1963 in international locations. The Conference ID is 2515873. A link to the live and archived webcast will also be available on the Investor Relations section of Omnicell's website at https://ir.omnicell.com/events-and-pr

      1/13/25 5:47:00 PM ET
      $OMCL
      Computer Manufacturing
      Technology
    • Omnicell to Present at the 43rd Annual J.P. Morgan Healthcare Conference

      Omnicell, Inc. (NASDAQ:OMCL), a leader in transforming the pharmacy care delivery model, announced that it will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025 at 1:30 p.m. PT. Live and archived webcasts of the presentation will be available through the Omnicell website at: https://ir.omnicell.com/events-and-presentations/ About Omnicell Since 1992, Omnicell has been committed to transforming pharmacy care through outcomes-centric innovation designed to optimize clinical and business outcomes across all settings of care. Through a comprehensive portfolio of robotics, smart devices, software, and expert services, Omnicell solutions are helpin

      1/8/25 4:01:00 PM ET
      $OMCL
      Computer Manufacturing
      Technology
    • Omnicell Announces OmniSphere

      Next-generation, cloud native, software workflow engine and data platform intended to seamlessly integrate enterprise robotics and smart devices across the continuum of care Company Showcases New and Enhanced Outcomes-Centric Innovation at ASHP Midyear 2024 Omnicell, Inc. (NASDAQ:OMCL) ("Omnicell" or the "Company"), a leader in transforming the pharmacy and nursing care delivery model, today announced OmniSphere, a next-generation, cloud native, software workflow engine and data platform. This groundbreaking new platform, designed to leverage the full power of a cloud native architecture, seamlessly integrates robotics and smart devices to support more secure, data-driven, medication ma

      12/9/24 8:30:00 AM ET
      $OMCL
      Computer Manufacturing
      Technology
    • Omnicell to Present at the Piper Sandler 36th Annual Healthcare Conference

      Omnicell, Inc. (NASDAQ:OMCL), a leader in transforming the pharmacy care delivery model, announced that it will present at the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3, 2024 at 2:00 p.m. ET. Live and archived webcasts of the presentation will be available through the Omnicell website at: https://ir.omnicell.com/events-and-presentations/ About Omnicell Since 1992, Omnicell has been committed to transforming pharmacy care through outcomes-centric innovation designed to optimize clinical and business outcomes across all settings of care. Through a comprehensive portfolio of robotics, smart devices, software, and expert services, Omnicell solutions are helpin

      11/22/24 4:01:00 PM ET
      $OMCL
      Computer Manufacturing
      Technology
    • Omnicell Announces Pricing of $150 Million Convertible Senior Notes Offering

      Omnicell, Inc. (NASDAQ:OMCL) ("Omnicell") today announced the pricing of $150.0 million aggregate principal amount of 1.00% Convertible Senior Notes due 2029 (the "notes") in a private placement (the "offering") to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). Omnicell also granted the initial purchasers of the notes an option to purchase, during a 13-day period beginning on, and including, the first date on which the notes are issued, up to an additional $22.5 million aggregate principal amount of notes. The sale of the notes is expected to close on November 22, 2024, subject to cu

      11/20/24 2:00:00 AM ET
      $OMCL
      Computer Manufacturing
      Technology
    • SEC Form SC 13G/A filed by Omnicell Inc. (Amendment)

      SC 13G/A - OMNICELL, INC. (0000926326) (Subject)

      12/11/23 9:36:42 AM ET
      $OMCL
      Computer Manufacturing
      Technology
    • SEC Form SC 13G/A filed by Omnicell Inc. (Amendment)

      SC 13G/A - OMNICELL, INC. (0000926326) (Subject)

      9/11/23 1:33:44 PM ET
      $OMCL
      Computer Manufacturing
      Technology
    • SEC Form SC 13G/A filed by Omnicell Inc. (Amendment)

      SC 13G/A - OMNICELL, INC. (0000926326) (Subject)

      2/9/23 11:27:45 AM ET
      $OMCL
      Computer Manufacturing
      Technology
    • SEC Form SC 13G/A filed by Omnicell Inc. (Amendment)

      SC 13G/A - OMNICELL, INC. (0000926326) (Subject)

      2/6/23 2:56:55 PM ET
      $OMCL
      Computer Manufacturing
      Technology
    • SEC Form SC 13G/A filed by Omnicell Inc. (Amendment)

      SC 13G/A - OMNICELL, Inc (0000926326) (Subject)

      2/10/22 8:28:05 AM ET
      $OMCL
      Computer Manufacturing
      Technology
    • SEC Form SC 13G/A filed by Omnicell Inc. (Amendment)

      SC 13G/A - OMNICELL, Inc (0000926326) (Subject)

      2/4/22 9:22:55 AM ET
      $OMCL
      Computer Manufacturing
      Technology
    • SEC Form SC 13G/A filed

      SC 13G/A - OMNICELL, Inc (0000926326) (Subject)

      2/10/21 11:40:09 AM ET
      $OMCL
      Computer Manufacturing
      Technology
    • Omnicell downgraded by BofA Securities with a new price target

      BofA Securities downgraded Omnicell from Buy to Neutral and set a new price target of $57.00 from $44.00 previously

      10/31/24 7:49:39 AM ET
      $OMCL
      Computer Manufacturing
      Technology
    • Omnicell upgraded by Barclays with a new price target

      Barclays upgraded Omnicell from Underweight to Equal Weight and set a new price target of $39.00 from $26.00 previously

      8/2/24 7:36:45 AM ET
      $OMCL
      Computer Manufacturing
      Technology
    • Barclays initiated coverage on Omnicell with a new price target

      Barclays initiated coverage of Omnicell with a rating of Underweight and set a new price target of $33.00

      1/3/24 8:05:18 AM ET
      $OMCL
      Computer Manufacturing
      Technology
    • Omnicell upgraded by Wells Fargo with a new price target

      Wells Fargo upgraded Omnicell from Underweight to Equal Weight and set a new price target of $28.00 from $39.00 previously

      11/3/23 7:22:06 AM ET
      $OMCL
      Computer Manufacturing
      Technology
    • Omnicell downgraded by BTIG Research

      BTIG Research downgraded Omnicell from Buy to Neutral

      11/3/23 7:21:35 AM ET
      $OMCL
      Computer Manufacturing
      Technology
    • Omnicell upgraded by Piper Sandler with a new price target

      Piper Sandler upgraded Omnicell from Neutral to Overweight and set a new price target of $39.00 from $70.00 previously

      11/3/23 7:21:04 AM ET
      $OMCL
      Computer Manufacturing
      Technology
    • Omnicell downgraded by KeyBanc Capital Markets

      KeyBanc Capital Markets downgraded Omnicell from Overweight to Sector Weight

      10/11/23 7:47:05 AM ET
      $OMCL
      Computer Manufacturing
      Technology
    • Wells Fargo reiterated coverage on Omnicell with a new price target

      Wells Fargo reiterated coverage of Omnicell with a rating of Underweight and set a new price target of $39.00 from $56.00 previously

      9/26/23 8:51:27 AM ET
      $OMCL
      Computer Manufacturing
      Technology
    • Omnicell downgraded by Piper Sandler with a new price target

      Piper Sandler downgraded Omnicell from Overweight to Neutral and set a new price target of $70.00 from $66.00 previously

      8/2/23 6:19:33 AM ET
      $OMCL
      Computer Manufacturing
      Technology
    • Omnicell downgraded by Wells Fargo with a new price target

      Wells Fargo downgraded Omnicell from Overweight to Underweight and set a new price target of $56.00 from $65.00 previously

      7/20/23 7:55:58 AM ET
      $OMCL
      Computer Manufacturing
      Technology

    Omnicell Inc. Leadership Updates

    Live Leadership Updates

    See more
    • Omnicell Appoints Nnamdi Njoku as Executive Vice President and Chief Operating Officer

      The Company taps business and operations executive with expertise that spans healthcare and med tech to help scale pharmacy automation and drive multi-year innovation and excellence Omnicell, Inc. (NASDAQ:OMCL) ("Omnicell" or the "Company"), a leader in transforming the pharmacy care delivery model, today announced that Nnamdi Njoku has been appointed Executive Vice President and Chief Operating Officer of the Company, effective October 7, 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240925324631/en/Nnamdi Njoku has been appointed Executive Vice President and Chief Operating Officer of Omnicell, effective October 7, 2024

      9/25/24 4:01:00 PM ET
      $OMCL
      Computer Manufacturing
      Technology
    • Clover Health Appoints Healthcare Technology Veteran Peter Kuipers as Chief Financial Officer

      FRANKLIN, Tenn., April 22, 2024 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover," "Clover Health" or the "Company"), a physician enablement technology company, today announced the appointment of Peter Kuipers as Chief Financial Officer ("CFO"), effective as of the day after the filing of the Company's Quarterly Report on Form 10-Q for the quarter-ended March 31, 2024. With a wealth of experience and a proven track record in financial management, Mr. Kuipers will drive strategic financial initiatives around profitability, growth and potential new revenue streams. Recognized with the 2018 San Francisco Bay Area Public Company CFO of the Year Award for small to me

      4/22/24 4:05:00 PM ET
      $CLOV
      $OMCL
      Medical Specialities
      Health Care
      Computer Manufacturing
      Technology
    • Omnicell Elects Eileen Voynick to Board of Directors

      Sales and Operational Veteran Brings Additional Global Business Experience and Healthcare Technology Expertise to Board Omnicell, Inc. (NASDAQ:OMCL) ("Omnicell" or the "Company"), a leader in transforming the pharmacy care delivery model, today announced that the Board of Directors elected Eileen Voynick to the Board, effective January 5, 2024. Ms. Voynick fills the vacancy resulting from Sara J. White, a Class I director who stepped down from the Company's Board of Directors, effective January 5, 2024. In addition, the Company announced that Vance Moore will not stand for reelection to the Company's Board at Omnicell's 2024 annual meeting of stockholders (the "2024 annual meeting") and e

      1/11/24 4:00:00 PM ET
      $MDRX
      $OMCL
      $CDK
      EDP Services
      Technology
      Computer Manufacturing
      Retail: Computer Software & Peripheral Equipment
    • Omnicell Appoints Bobby Ghoshal to Board of Directors

      Established Leader Brings Global SaaS and Healthcare Technology Experience to Board Omnicell, Inc. (NASDAQ:OMCL) ("Omnicell" or the "Company"), a leader in transforming the pharmacy care delivery model, today announced it has increased its number of board seats from 9 to 10, and has appointed Kaushik "Bobby" Ghoshal to fill the newest seat as an independent director of Omnicell's Board of Directors, effective immediately. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230711576271/en/Omnicell Appoints Bobby Ghoshal to Board of Directors (Photo: Business Wire) Mr. Ghoshal is an established technology leader who brings more than

      7/11/23 8:30:00 AM ET
      $OMCL
      Computer Manufacturing
      Technology
    • Omnicell Appoints Nchacha E. Etta as Executive Vice President and Chief Financial Officer

      Seasoned Leader Brings Over Two Decades of Finance and Accounting Experience to Omnicell Omnicell, Inc. (NASDAQ:OMCL) ("Omnicell" or the "Company"), a leader in transforming the pharmacy care delivery model, today announced that Nchacha E. Etta has been appointed Executive Vice President and Chief Financial Officer of the Company, effective June 1, 2023. Mr. Etta succeeds Peter J. Kuipers, who, as previously announced, will be stepping down from his role as Executive Vice President and Chief Financial Officer. Mr. Kuipers will remain with the Company through July 1, 2023, to help ensure a smooth transition of responsibilities. This press release features multimedia. View the full release

      5/15/23 4:01:00 PM ET
      $OMCL
      Computer Manufacturing
      Technology
    • Omnicell Appoints Edward Bousa to Board of Directors

      Omnicell, Inc. (NASDAQ:OMCL), a leading provider of medication management solutions and adherence tools for health systems and pharmacies, today announced it has increased its number of board seats from 9 to 10, and has appointed Edward P. Bousa to fill the newest seat of the Company's Board of Directors, effective immediately. Mr. Bousa will serve as an independent director and as a member of the Board's Corporate Governance Committee. Mr. Bousa is a renowned value portfolio manager who brings nearly four decades of experience in institutional asset management, including 20 years at Wellington Management Company, a leading investment management firm. Prior to his retirement in 2020, Mr. B

      7/12/21 8:31:00 AM ET
      $OMCL
      Computer Manufacturing
      Technology
    • Omnicell Appoints Christine Mellon as Chief People Officer

      MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Omnicell, Inc. (Nasdaq:OMCL), a leading provider of medication management solutions and adherence tools for health systems and pharmacies, today announced that Christine Mellon has joined the company as Executive Vice President, Chief People Officer. Bringing more than 25 years of human resources, organizational, and cultural transformation leadership, Ms. Mellon will lead human resources functions, employee environments, and internal communications for Omnicell’s global operations. “As Omnicell continues to transform the pharmacy care delivery model to deliver on the vision of Autonomous Pharmacy, Christine’s role will be pivotal to shapin

      2/22/21 8:30:00 AM ET
      $OMCL
      Computer Manufacturing
      Technology

    Omnicell Inc. Financials

    Live finance-specific insights

    See more
    • Omnicell Announces First Quarter 2025 Results

      Omnicell delivers solid first quarter financial results Results exceed previously issued first quarter 2025 guidance for total revenues and non-GAAP EPS Updates full year 2025 non-GAAP EBITDA and non-GAAP EPS guidance Omnicell, Inc. (NASDAQ:OMCL) ("Omnicell," "we," "our," "us," "management," or the "Company"), a leader in transforming the pharmacy and nursing care delivery model, today announced results for its first quarter ended March 31, 2025. "We delivered strong financial results for the first quarter of 2025, exceeding our previously provided guidance ranges for both revenue and earnings, which we believe reflects customers embracing the industry-defined vision of the Autonomous P

      5/6/25 6:30:00 AM ET
      $OMCL
      Computer Manufacturing
      Technology
    • Omnicell to Release First Quarter 2025 Financial Results on May 6, 2025

      Omnicell, Inc. (NASDAQ:OMCL), a leader in transforming the pharmacy and nursing care delivery model, will release its financial results for the first quarter 2025, before market open on Tuesday, May 6, 2025. The Company will host a conference call and webcast to discuss its financial results at 8:30 a.m. ET that same day. All interested parties are invited to listen to the live call and presentation by dialing (800) 715-9871 in the U.S. or (646) 307-1963 in international locations. The Conference ID is 7437144. A link to the live and archived webcast will also be available on the Investor Relations section of Omnicell's website at https://ir.omnicell.com/events-and-presentations/. About O

      4/14/25 4:01:00 PM ET
      $OMCL
      Computer Manufacturing
      Technology
    • Omnicell Announces Fiscal Year and Fourth Quarter 2024 Results

      Omnicell delivers strong fourth quarter financial results Results exceed previously issued full year guidance for bookings, total revenues, and non-GAAP EBITDA Omnicell, Inc. (NASDAQ:OMCL) ("Omnicell," "we," "our," "us," "management," or the "Company"), a leader in transforming the pharmacy and nursing care delivery model, today announced results for its fiscal year and fourth quarter ended December 31, 2024. "We delivered solid financial results for the fourth quarter of 2024, including returning to year-over-year revenue growth. We are pleased with the improved execution of the business throughout 2024, including strong free cash flows achieved in the year," stated Randall Lipps, ch

      2/6/25 6:30:00 AM ET
      $OMCL
      Computer Manufacturing
      Technology
    • Omnicell to Release Fourth Quarter and Full Year 2024 Financial Results on February 6, 2025

      Omnicell, Inc. (NASDAQ:OMCL), a leader in transforming the pharmacy and nursing care delivery model, will release its financial results for the fourth quarter and full year 2024, before market open on Thursday, February 6, 2025. The Company will host a conference call and webcast to discuss its financial results at 8:30 a.m. ET that same day. All interested parties are invited to listen to the live call and presentation by dialing (800) 715-9871 in the U.S. or (646) 307-1963 in international locations. The Conference ID is 2515873. A link to the live and archived webcast will also be available on the Investor Relations section of Omnicell's website at https://ir.omnicell.com/events-and-pr

      1/13/25 5:47:00 PM ET
      $OMCL
      Computer Manufacturing
      Technology
    • Omnicell Announces Third Quarter 2024 Results

      Omnicell delivers solid third quarter financial results Total revenues of $282 million GAAP net income per diluted share of $0.19 Non-GAAP net income per diluted share of $0.56 Raises 2024 non-GAAP EBITDA and non-GAAP earnings per share guidance Omnicell, Inc. (NASDAQ:OMCL) ("Omnicell," "we," "our," "us," "management," or the "Company"), a leader in transforming the pharmacy care delivery model, today announced results for its third quarter ended September 30, 2024. Randall Lipps, chairman, president, chief executive officer, and founder of Omnicell, said, "We are pleased to deliver another consecutive quarter of solid financial performance, with results within or exceeding each of ou

      10/30/24 6:30:00 AM ET
      $OMCL
      Computer Manufacturing
      Technology
    • Omnicell to Release Third Quarter 2024 Financial Results on October 30, 2024

      Omnicell, Inc. (NASDAQ:OMCL), a leader in transforming the pharmacy care delivery model, will release its financial results for the third quarter 2024, before market open on Wednesday, October 30, 2024. The Company will host a conference call and webcast to discuss its financial results at 8:30 a.m. ET that same day. All interested parties are invited to listen to the live call and presentation by dialing (800) 715-9871 in the U.S. or (646) 307-1963 in international locations. The Conference ID is 6944646. A link to the live and archived webcast will also be available on the Investor Relations section of Omnicell's website at https://ir.omnicell.com/events-and-presentations/. About Omnice

      10/7/24 5:35:00 PM ET
      $OMCL
      Computer Manufacturing
      Technology
    • Omnicell Announces Second Quarter 2024 Results

      Results exceed previously issued second quarter guidance across all metrics Total revenues of $277 million GAAP net income per diluted share of $0.08 Non-GAAP net income per diluted share of $0.51 Raises 2024 non-GAAP EBITDA and non-GAAP earnings per share guidance Omnicell, Inc. (NASDAQ:OMCL) ("Omnicell," "we," "our," "us," "management," or the "Company"), a leader in transforming the pharmacy care delivery model, today announced results for its second quarter ended June 30, 2024. Randall Lipps, chairman, president, chief executive officer, and founder of Omnicell, said, "We are pleased with the second quarter results that we announced today, which exceeded our previously issue

      8/1/24 6:30:00 AM ET
      $OMCL
      Computer Manufacturing
      Technology
    • Omnicell to Release Second Quarter 2024 Financial Results on August 1, 2024

      Omnicell, Inc. (NASDAQ:OMCL), a leader in transforming the pharmacy care delivery model, will release its financial results for the second quarter 2024, before market open on Thursday, August 1, 2024. The Company will host a conference call and webcast to discuss its financial results at 8:30 a.m. ET that same day. All interested parties are invited to listen to the live call and presentation by dialing (800) 715-9871 in the U.S. or (646) 307-1963 in international locations. The Conference ID is 3278878. A link to the live and archived webcast will also be available on the Investor Relations section of Omnicell's website at https://ir.omnicell.com/events-and-presentations/. About Omnice

      7/15/24 4:01:00 PM ET
      $OMCL
      Computer Manufacturing
      Technology
    • Omnicell Announces First Quarter 2024 Results

      Results exceed prior first quarter guidance across all metrics Total GAAP revenues of $246 million Omnicell, Inc. (NASDAQ:OMCL) ("Omnicell," "we," "our," "us," "management," or the "Company"), a leader in transforming the pharmacy care delivery model, today announced results for its first quarter ended March 31, 2024. Randall Lipps, chairman, president, chief executive officer, and founder of Omnicell, said, "We are pleased with the first quarter results that we announced today, which exceeded our previously issued guidance across all key metrics, including revenue, non-GAAP EBITDA and non-GAAP earnings per share." "As we have navigated through a challenging customer environment, we

      5/2/24 7:30:00 AM ET
      $OMCL
      Computer Manufacturing
      Technology
    • Omnicell to Release First Quarter 2024 Financial Results on May 2, 2024

      Omnicell, Inc. (NASDAQ:OMCL), a leader in transforming the pharmacy care delivery model, will release its financial results for the first quarter 2024, before market open on Thursday, May 2, 2024. The Company will host a conference call and webcast to discuss its financial results at 8:30 a.m. ET that same day. All interested parties are invited to listen to the live call and presentation by dialing (888) 550-5424 in the U.S. or (646) 960-0819 in international locations. The Conference ID is 9581556. A link to the live and archived webcast will also be available on the Investor Relations section of Omnicell's website at https://ir.omnicell.com/events-and-presentations/. About Omnicell

      4/8/24 4:01:00 PM ET
      $OMCL
      Computer Manufacturing
      Technology